Skip to main content
Clinical Trials/NCT05996575
NCT05996575
Completed
Not Applicable

IMPACT: Investigating Mild Cognitive Impairment in Patients And Controls With TD-fNIRS

Kernel4 sites in 1 country133 target enrollmentJuly 25, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild Cognitive Impairment
Sponsor
Kernel
Enrollment
133
Locations
4
Primary Endpoint
Brain hemodynamic activity with TD-fNIRS
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of the proposed observational, multi-site study is to use fNIRS neurophysiological data recorded during a battery of tasks to detect MCI within a cohort consisting of patients and age-matched healthy controls. Furthermore, the investigators aim to explore whether they can measure the severity of MCI symptoms in the patient population. If successful, this approach enables clinicians to track the disease at its source-the brain; possibly allowing for earlier detection of MCI and its progression, and ultimately more efficient interventions.

Registry
clinicaltrials.gov
Start Date
July 25, 2023
End Date
June 13, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Kernel
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Must have a diagnosis of MCI (amnesiac or non-amnesiac) as determined by clinician
  • Adults (older adults) between the ages of 55-85 years inclusive at time of enrollment
  • Ability to perform informed consent on their own
  • Fluent in English (speaking and reading)
  • Healthy Controls
  • Adults (older adults) between the ages of 55-85 years inclusive at time of enrollment
  • Ability to perform informed consent on their own
  • Fluent in English (speaking and reading)

Exclusion Criteria

  • Alzheimer's or dementia diagnosis
  • Current substance or alcohol dependence, and/or alcohol or substance abuse as determined by CAGE-AID assessment for drug and alcohol abuse. A score of 2 or higher would result in exclusion.
  • Has uncorrected major visual or auditory deficits that would prevent them from completing a study task
  • Current or recent (in the past 6 months) chemotherapy and/or radiation for any cancer
  • Major medical illnesses and psychiatric conditions (other than MCI) including:
  • Severe/uncontrolled Diabetes, hypertension and hypothyroidism that could pose secondary causes of cognitive decline
  • Parkinson's disease
  • Motor neuron diseases
  • Multiple Sclerosis
  • Brain Tumor

Outcomes

Primary Outcomes

Brain hemodynamic activity with TD-fNIRS

Time Frame: About 1 hour during the study visit

This includes changes in the concentration of oxygenated and deoxygenated hemoglobin as measured by the change in light absorption.

Optical properties of the brain with TD-fNIRS

Time Frame: About 1 hour during the study visit

This measures how much light is absorbed at different points on the head.

Physiological features with TD-fNIRS

Time Frame: About 1 hour during the study visit

This includes cardiac measures, such as heart rate (HR) and heart rate variability (HRV).

Secondary Outcomes

  • Mini-Mental State Evaluation (MMSE)(Within 6 months of the study visit)
  • Geriatric Depression Scale (Short Form)(About 30 minutes during the study visit)
  • Mini-Cog(About 30 minutes during the study visit)
  • Apathy Evaluation Scale(About 30 minutes during the study visit)
  • General Anxiety Disorder(About 30 minutes during the study visit)
  • Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS ADL-MCI)(About 30 minutes during the study visit)

Study Sites (4)

Loading locations...

Similar Trials